Indicator type;Size of the company;Total
Number of companies carrying out R&D in Biotechnology;Less than 250 employees;1,431
Number of companies carrying out R&D in Biotechnology;250 and more employees;172
Number of companies carrying out R&D in Biotechnology;Total;1,602
% Companies by type of biotechnology used: Genetic Code;Less than 250 employees;27.2
% Companies by type of biotechnology used: Genetic Code;250 and more employees;41.7
% Companies by type of biotechnology used: Genetic Code;Total;28.8
% Companies by type of biotechnology used: Functional Units;Less than 250 employees;37.6
% Companies by type of biotechnology used: Functional Units;250 and more employees;50.1
% Companies by type of biotechnology used: Functional Units;Total;38.9
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Less than 250 employees;19.6
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;250 and more employees;36.9
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Total;21.5
% Companies by type of biotechnology used: Bioprocesses;Less than 250 employees;47.2
% Companies by type of biotechnology used: Bioprocesses;250 and more employees;69.4
% Companies by type of biotechnology used: Bioprocesses;Total;49.5
% Companies by type of biotechnology used: Subcellular Organisms;Less than 250 employees;7.5
% Companies by type of biotechnology used: Subcellular Organisms;250 and more employees;18.7
% Companies by type of biotechnology used: Subcellular Organisms;Total;8.7
% Companies by type of biotechnology used: Bioinformatics;Less than 250 employees;26.3
% Companies by type of biotechnology used: Bioinformatics;250 and more employees;31.3
% Companies by type of biotechnology used: Bioinformatics;Total;26.9
% Companies by type of biotechnology used: Nanobiotechnology;Less than 250 employees;11.6
% Companies by type of biotechnology used: Nanobiotechnology;250 and more employees;13.6
% Companies by type of biotechnology used: Nanobiotechnology;Total;11.8
% Companies by type of biotechnology used: Other;Less than 250 employees;17.9
% Companies by type of biotechnology used: Other;250 and more employees;18.4
% Companies by type of biotechnology used: Other;Total;18.0
Companies in which biotechnology activities are: Main and/or exclusive;Less than 250 employees;745
Companies in which biotechnology activities are: Main and/or exclusive;250 and more employees;28
Companies in which biotechnology activities are: Main and/or exclusive;Total;773
Companies in which biotechnology activities are: A secondary business line;Less than 250 employees;223
Companies in which biotechnology activities are: A secondary business line;250 and more employees;56
Companies in which biotechnology activities are: A secondary business line;Total;279
Companies in which biotechnology activities are: A necessary tool for production;Less than 250 employees;463
Companies in which biotechnology activities are: A necessary tool for production;250 and more employees;88
Companies in which biotechnology activities are: A necessary tool for production;Total;550
% Companies by final application areas of biotechnology use: Human Health;Less than 250 employees;49.2
% Companies by final application areas of biotechnology use: Human Health;250 and more employees;41.0
% Companies by final application areas of biotechnology use: Human Health;Total;48.4
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Less than 250 employees;19.5
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;250 and more employees;16.0
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Total;19.1
% Companies by final application areas of biotechnology use: Food Products;Less than 250 employees;27.7
% Companies by final application areas of biotechnology use: Food Products;250 and more employees;38.9
% Companies by final application areas of biotechnology use: Food Products;Total;28.9
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Less than 250 employees;25.0
% Companies by final application areas of biotechnology use: Agriculture and Forestry;250 and more employees;23.1
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Total;24.8
% Companies by final application areas of biotechnology use: Environment;Less than 250 employees;17.8
% Companies by final application areas of biotechnology use: Environment;250 and more employees;21.3
% Companies by final application areas of biotechnology use: Environment;Total;18.2
% Companies by final application areas of biotechnology use: Industry;Less than 250 employees;13.0
% Companies by final application areas of biotechnology use: Industry;250 and more employees;17.7
% Companies by final application areas of biotechnology use: Industry;Total;13.5
R&D personnel in Biotechnology (PP);Less than 250 employees;11,534
R&D personnel in Biotechnology (PP);250 and more employees;7,773
R&D personnel in Biotechnology (PP);Total;19,307
R&D personnel in Biotechnology (PP): Research personnel;Less than 250 employees;7,003
R&D personnel in Biotechnology (PP): Research personnel;250 and more employees;3,776
R&D personnel in Biotechnology (PP): Research personnel;Total;10,779
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Less than 250 employees;4,531
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;250 and more employees;3,998
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Total;8,528
R&D personnel in Biotechnology (PP). Women;Less than 250 employees;6,249
R&D personnel in Biotechnology (PP). Women;250 and more employees;4,905
R&D personnel in Biotechnology (PP). Women;Total;11,155
R&D personnel in Biotechnology (PP). Women: Research personnel;Less than 250 employees;3,719
R&D personnel in Biotechnology (PP). Women: Research personnel;250 and more employees;2,215
R&D personnel in Biotechnology (PP). Women: Research personnel;Total;5,934
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Less than 250 employees;2,530
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;250 and more employees;2,692
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Total;5,222
R&D personnel in Biotechnology (FTE);Less than 250 employees;8,166.7
R&D personnel in Biotechnology (FTE);250 and more employees;5,927.0
R&D personnel in Biotechnology (FTE);Total;14,093.7
R&D personnel in Biotechnology (FTE): Research personnel;Less than 250 employees;5,144.6
R&D personnel in Biotechnology (FTE): Research personnel;250 and more employees;2,929.2
R&D personnel in Biotechnology (FTE): Research personnel;Total;8,073.8
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Less than 250 employees;3,022.0
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;250 and more employees;2,997.9
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Total;6,019.9
R&D personnel in Biotechnology (FTE). Women;Less than 250 employees;4,526.9
R&D personnel in Biotechnology (FTE). Women;250 and more employees;3,778.8
R&D personnel in Biotechnology (FTE). Women;Total;8,305.8
R&D personnel in Biotechnology (FTE). Women: Research personnel;Less than 250 employees;2,784.5
R&D personnel in Biotechnology (FTE). Women: Research personnel;250 and more employees;1,698.0
R&D personnel in Biotechnology (FTE). Women: Research personnel;Total;4,482.6
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Less than 250 employees;1,742.4
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;250 and more employees;2,080.8
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Total;3,823.2
Expenditure on internal R&D in Biotechnology (thousands of euros);Less than 250 employees;829,158
Expenditure on internal R&D in Biotechnology (thousands of euros);250 and more employees;633,537
Expenditure on internal R&D in Biotechnology (thousands of euros);Total;1,462,695
1) By type of expenditure: Current expenditure;Less than 250 employees;741,967
1) By type of expenditure: Current expenditure;250 and more employees;605,608
1) By type of expenditure: Current expenditure;Total;1,347,574
1.1) Labour expenditure of research personnel;Less than 250 employees;284,732
1.1) Labour expenditure of research personnel;250 and more employees;185,982
1.1) Labour expenditure of research personnel;Total;470,714
1.2) Labour expenditure of technical and auxiliary personnel;Less than 250 employees;129,850
1.2) Labour expenditure of technical and auxiliary personnel;250 and more employees;128,941
1.2) Labour expenditure of technical and auxiliary personnel;Total;258,791
1.3) Other current expenditure;Less than 250 employees;327,385
1.3) Other current expenditure;250 and more employees;290,684
1.3) Other current expenditure;Total;618,069
2) By type of expenditure: Capital expenditure;Less than 250 employees;87,192
2) By type of expenditure: Capital expenditure;250 and more employees;27,929
2) By type of expenditure: Capital expenditure;Total;115,121
2.1) Land and buildings;Less than 250 employees;13,513
2.1) Land and buildings;250 and more employees;8,365
2.1) Land and buildings;Total;21,877
2.2) Equipment and tools;Less than 250 employees;36,847
2.2) Equipment and tools;250 and more employees;17,744
2.2) Equipment and tools;Total;54,592
2.3) Acquisition of specific R&D software;Less than 250 employees;3,675
2.3) Acquisition of specific R&D software;250 and more employees;998
2.3) Acquisition of specific R&D software;Total;4,673
2.4) Other R&D-specific IP products;Less than 250 employees;33,156
2.4) Other R&D-specific IP products;250 and more employees;822
2.4) Other R&D-specific IP products;Total;33,978
1.1) By origin of funds: Own funds;Less than 250 employees;538,664
1.1) By origin of funds: Own funds;250 and more employees;474,841
1.1) By origin of funds: Own funds;Total;1,013,505
1.2) By origin of funds: Funds from the Business sector;Less than 250 employees;129,527
1.2) By origin of funds: Funds from the Business sector;250 and more employees;76,545
1.2) By origin of funds: Funds from the Business sector;Total;206,072
1.3) By origin of funds: Funds from the Public Administration sector;Less than 250 employees;108,718
1.3) By origin of funds: Funds from the Public Administration sector;250 and more employees;49,989
1.3) By origin of funds: Funds from the Public Administration sector;Total;158,706
1.4) By origin of funds: Funds from the Higher Education sector;Less than 250 employees;615
1.4) By origin of funds: Funds from the Higher Education sector;250 and more employees;0
1.4) By origin of funds: Funds from the Higher Education sector;Total;615
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Less than 250 employees;2,957
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;250 and more employees;6,871
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Total;9,828
1.6) By origin of funds: Funds from the rest of the world;Less than 250 employees;48,678
1.6) By origin of funds: Funds from the rest of the world;250 and more employees;25,290
1.6) By origin of funds: Funds from the rest of the world;Total;73,969
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Less than 250 employees;45,153
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);250 and more employees;51,085
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Total;96,238
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Less than 250 employees;22,799
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;250 and more employees;42,565
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Total;65,364
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Less than 250 employees;22,353
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;250 and more employees;8,521
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Total;30,874
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Less than 250 employees;48.6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;250 and more employees;25.0
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Total;46.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Less than 250 employees;17.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;250 and more employees;16.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Total;17.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Less than 250 employees;26.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;250 and more employees;21.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Total;25.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Less than 250 employees;13.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;250 and more employees;13.0
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Total;13.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Less than 250 employees;19.6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;250 and more employees;10.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Total;18.6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Less than 250 employees;18.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;250 and more employees;8.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Total;17.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Less than 250 employees;20.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;250 and more employees;17.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Total;20.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Less than 250 employees;48.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;250 and more employees;39.0
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Total;47.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Less than 250 employees;54.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;250 and more employees;47.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Total;53.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Less than 250 employees;21.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;250 and more employees;19.6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Total;21.6
% Companies with international revenues related to biotechnology activities;Less than 250 employees;21.6
% Companies with international revenues related to biotechnology activities;250 and more employees;27.2
% Companies with international revenues related to biotechnology activities;Total;22.2
% Companies representing international revenues related to biotechnology activities;Less than 250 employees;7.2
% Companies representing international revenues related to biotechnology activities;250 and more employees;1.7
% Companies representing international revenues related to biotechnology activities;Total;2.2
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Less than 250 employees;46.3
% International revenues related to biotechnology activities distributed in: Revenues from the EU;250 and more employees;59.0
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Total;55.2
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Less than 250 employees;53.7
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;250 and more employees;41.0
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Total;44.8
% International revenues related to biotechnology activities by classification: International trade in goods and services;Less than 250 employees;83.3
% International revenues related to biotechnology activities by classification: International trade in goods and services;250 and more employees;88.8
% International revenues related to biotechnology activities by classification: International trade in goods and services;Total;87.2
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Less than 250 employees;2.9
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;250 and more employees;5.3
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;4.6
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Less than 250 employees;0.6
% International revenues related to biotechnology activities by classification: Subsidies from external sources;250 and more employees;6.0
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Total;4.3
% International revenues related to biotechnology activities by classification: Other;Less than 250 employees;13.2
% International revenues related to biotechnology activities by classification: Other;250 and more employees;0.0
% International revenues related to biotechnology activities by classification: Other;Total;3.9